Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-y1]-5-methy1-2- thieny1}carbony1)pyrimidin-4-y1]amino}-2-hydroxycyclopenty1]methyl sulfamate or a pharmaceutically acceptable salt, in combination with one or more checkpoint inhibitors. Also provided are medicaments for use in treating cancer.